Create Possibilities*

HUMIRA (adalimumab) helps treat the pain and inflammation of certain autoimmune conditions and could be right for you if you still have symptoms despite your current treatment.

ˇ
 
 
 
 
 
 
 
 

Humira treats these autoimmune conditions

 

Rheumatoid Arthritis

HUMIRA helps reduce pain and slow down further joint damage in adults with moderate to severe rheumatoid arthritis.

 

 

Crohn’s disease

HUMIRA has been proven to induce and maintain remission (little or no symptoms) in a number of people with moderate to severe Crohn’s disease.

 

Ankylosing spondylitis

HUMIRA can help reduce the back pain and stiffness of ankylosing spondylitis. It is expected that over 50% of people may have a reduction in symptoms after 12 weeks of treatment.7,§

 

Psoriatic arthritis

HUMIRA helps to reduce the joint pain and skin symptoms of psoriatic arthritis.

 

 

Psoriasis

7 out of 10 adults with moderate to severe plaque psoriasis on HUMIRA can expect a 75% reduction in skin symptoms (severity and/or extent) after just four months.10,11,§

 

 

Juvenile idiopathic arthritis

HUMIRA helps reduce pain, stiffness and swelling in children with moderate to severe polyarticular juvenile idiopathic arthritis.

 

Rheumatoid Arthritis

HUMIRA helps reduce pain and stop further joint damage in many adults with moderate to severe rheumatoid arthritis.2,3

 

Ankylosing spondylitis

HUMIRA can help reduce the back pain and stiffness of ankylosing spondylitis. It is expected that over 50% of people may have a reduction in symptoms after 12 weeks of treatment.7

 

 

Psoriasis

7 out of 10 people on HUMIRA can expect a 75% reduction in skin symptoms (severity and/or extent) after just four months.10,11

 

Crohn’s disease

HUMIRA has been proven to induce and maintain remission (little or no symptoms) in a number of people with moderate to severe Crohn’s disease.4-6

 

Psoriatic arthritis

HUMIRA helps to reduce the joint pain and skin symptoms of psoriatic arthritis.8,9

 

 

Juvenile idiopathic arthritis

HUMIRA helps reduce pain, stiffness and swelling in children with moderate to severe polyarticular juvenile idiopathic arthritis.12,13

 

Starting and taking HUMIRA

What you need to know about taking HUMIRA, including free support to help you get the best out of your HUMIRA treatment.

 

For healthcare professionals

Resources specifically for healthcare professionals managing HUMIRA patients.

 

Safety information

Important safety information to know about HUMIRA.

 

§ Individual results may vary.

*AbbVie medications and programmes are designed to support patients on their health journey.

References:

  1. Approved HUMIRA Pen CMI.
  2. Weinblatt, M.E. et al. Arthritis & Rheumatism 2003;48(1):35-45
  3. Keystone E C, et al. Arthritis Rheum 2004;50(5):1400-1411
  4. Hanauer S et al. Gastroenterol 2006;130:323–333.
  5. Colombel JF, et al. Gastroenterol. 2007;132(1):52-65.
  6. Panaccione R, et al. Aliment Pharmacol Ther 2013;1-12.
  7. van der Heijde D et al. Arth & Rheum. 2006;54(7):2136-46
  8. Mease P. J., et al. Arthritis Rheum. 2005;52:3279–89
  9. Gladman D, et al. J Rheumatol 2010;37:1898-1906
  10. Saurat J H, et al. Br J Dermatol 2008;158:558-66
  11. Menter, A et al. J Am Acad Dermatol 2008;58:106-15
  12. Lovell, DJ et al. N Engl J Med 2008;359:810-20
  13. Schmeling, H. et al. Arth Rheum 2014;66:2580-89

NZ-HUM-0184. TAPS PP2498. August 2018.

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use, pre-filled syringe (containing 20mg adalimumab) or single-use pen (containing 20mg or 40mg adalimumab). It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, chronic plaque psoriasis, ulcerative colitis, Crohn’s disease, non-infectious intermediate, posterior or pan-uveitis in adults, chronic non-infectious anterior uveitis in children >2, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a fully funded medicine under Special Authority for most indications- normal pharmacy prescription charges apply. HUMIRA is not funded for enthesitis-related arthritis, non-radiographic axial spondyloarthritis, ulcerative colitis, uveitis and hidradenitis suppurativa – a pharmacy charge will apply. Normal doctor’s charges apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | Medsafe HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.

NZ-HUM-0181 TAPS PP2498 Last updated: August 2018. Copyright © AbbVie Limited.